NCT01805037 2021-09-01Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ LymphomasNorthwestern UniversityPhase 1/2 Terminated20 enrolled 17 charts
NCT00089076 2014-05-30MDX-010 in Treating Patients With Recurrent or Refractory LymphomaNational Cancer Institute (NCI)Phase 1/2 Terminated18 enrolled 11 charts